Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-13
2005-12-13
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S427000
Reexamination Certificate
active
06974831
ABSTRACT:
A novel class of cycloalkyl fused indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
REFERENCES:
patent: 5639778 (1997-06-01), Andersson et al.
patent: 5684034 (1997-11-01), Bach et al.
patent: 6831095 (2004-12-01), Harper et al.
patent: 0 620 214 (1994-10-01), None
patent: WO 94/21608 (1994-09-01), None
patent: WO 00/10568 (2000-03-01), None
patent: WO 00/69818 (2000-11-01), None
Beight Douglas Wade
Kinnick Michael Dean
Lin Ho-Shen
Morin John Michael
Richett Michael Enrico
Eli Lilly and Company
Ginah Francis O.
Shameem Golam M. M.
LandOfFree
sPLA2 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with sPLA2 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and sPLA2 inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3468164